8
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Gender Differences in Alzheimer Disease: Brain Atrophy, Histopathology Burden, and Cognition

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Multiple studies suggest that females are affected by Alzheimer disease (AD) more severely and more frequently than males. Other studies have failed to confirm this and the issue remains controversial. Difficulties include differences in study methods and male versus female life expectancy. Another element of uncertainty is that the majority of studies have lacked neuropathological confirmation of the AD diagnosis. We compared clinical and pathological AD severity in 1028 deceased subjects with full neuropathological examinations. The age of dementia onset did not differ by gender but females were more likely to proceed to very severe clinical and pathological disease, with significantly higher proportions having a Mini-Mental State Examination score of 5 or less and Braak stage VI neurofibrillary degeneration. Median neuritic plaque densities were similar in females and males with AD but females had significantly greater tangle density scores. In addition, we found that AD-control brain weight differences were significantly greater for females, even after adjustment for age, disease duration, and comorbid conditions. These findings suggest that when they are affected by AD, females progress more often to severe cognitive dysfunction, due to more severe neurofibrillary degeneration, and greater loss of brain parenchyma.

          Related collections

          Most cited references49

          • Record: found
          • Abstract: found
          • Article: not found

          National Institute on Aging-Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease: a practical approach.

          We present a practical guide for the implementation of recently revised National Institute on Aging-Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease (AD). Major revisions from previous consensus criteria are: (1) recognition that AD neuropathologic changes may occur in the apparent absence of cognitive impairment, (2) an "ABC" score for AD neuropathologic change that incorporates histopathologic assessments of amyloid β deposits (A), staging of neurofibrillary tangles (B), and scoring of neuritic plaques (C), and (3) more detailed approaches for assessing commonly co-morbid conditions such as Lewy body disease, vascular brain injury, hippocampal sclerosis, and TAR DNA binding protein (TDP)-43 immunoreactive inclusions. Recommendations also are made for the minimum sampling of brain, preferred staining methods with acceptable alternatives, reporting of results, and clinico-pathologic correlations.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            alpha-Synuclein is phosphorylated in synucleinopathy lesions.

            The deposition of the abundant presynaptic brain protein alpha-synuclein as fibrillary aggregates in neurons or glial cells is a hallmark lesion in a subset of neurodegenerative disorders. These disorders include Parkinson's disease (PD), dementia with Lewy bodies (DLB) and multiple system atrophy, collectively referred to as synucleinopathies. Importantly, the identification of missense mutations in the alpha-synuclein gene in some pedigrees of familial PD has strongly implicated alpha-synuclein in the pathogenesis of PD and other synucleinopathies. However, specific post-translational modifications that underlie the aggregation of alpha-synuclein in affected brains have not, as yet, been identified. Here, we show by mass spectrometry analysis and studies with an antibody that specifically recognizes phospho-Ser 129 of alpha-synuclein, that this residue is selectively and extensively phosphorylated in synucleinopathy lesions. Furthermore, phosphorylation of alpha-synuclein at Ser 129 promoted fibril formation in vitro. These results highlight the importance of phosphorylation of filamentous proteins in the pathogenesis of neurodegenerative disorders.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Sex differences in the clinical manifestations of Alzheimer disease pathology.

              Sex differences in risk of clinically diagnosed Alzheimer disease (AD) have been studied extensively, but little is known about the relation of the pathologic indices of AD to the clinical manifestations of the disease in men compared with women. To test whether the relation of AD pathology to the clinical manifestations of the disease differs in men and women. Longitudinal, clinicopathologic cohort study. Analyses were conducted on 141 older Catholic clergy members who underwent detailed annual clinical evaluations and brain autopsy at death. The number of neuritic plaques, diffuse plaques, and neurofibrillary tangles in a 1-mm2 area sampled from 4 cortical regions was counted, and a global measure of AD pathology (range, 0-2.98 U) and specific measures of each pathology were derived. Clinical diagnosis of probable AD and level of global cognitive function at the last evaluation before death. Women had more global AD pathology than did men (P = .04), due primarily to more neurofibrillary tangles (P = .02). At the last evaluation before death, 57 persons met clinical criteria for probable AD (34 [60%] of them women). In logistic regression models, sex was not related to odds of clinical AD (odds ratio [OR], 1.35; 95% confidence interval [CI], 0.56-3.25), but the relation of global AD pathology to clinical diagnosis differed for men and women. Each additional unit of AD pathology was associated with a nearly 3-fold increase in the odds of clinical AD in men (OR, 2.82; 95% CI, 1.03-7.65) compared with a more than 20-fold increase in the odds of clinical AD in women (OR, 22.67; 95% CI, 5.11-100.53). Results were unchanged after controlling for potential confounders or using level of cognition as the outcome. These data suggest that AD pathology is more likely to be clinically expressed as dementia in women than in men.
                Bookmark

                Author and article information

                Journal
                J Neuropathol Exp Neurol
                J. Neuropathol. Exp. Neurol
                jnen
                jnen
                Journal of Neuropathology and Experimental Neurology
                Oxford University Press
                0022-3069
                1554-6578
                August 2016
                11 June 2016
                11 June 2016
                : 75
                : 8
                : 748-754
                Affiliations
                [1 ]From the Banner Sun Health Research Institute, Sun City, Arizona (JRF, AJI, LIS, KJD, CMB, SJ, TGB, GES);
                [2 ]Department of Economics, Arizona State University, Tempe, Arizona (EVA, JW);
                [3 ]Neurological Institute, Phoenix, Arizona (MNS);
                [4 ]Mayo Clinic Arizona, Scottsdale, Arizona (RJC, CHA, BKW, ED-D);
                [5 ]Department of Neurology, University of Arizona, Tucson, Arizona (SZR, GLA);
                [6 ]Banner Alzheimer Institute, Phoenix, Arizona (ADB, KC, EMR).
                Author notes

                This project was supported by the National Institute of Neurological Disorders and Stroke (U24 NS072026 National Brain and Tissue Resource for Parkinson's Disease and Related Disorders), the National Institute on Aging (P30 AG19610 Arizona Alzheimer's Disease Core Center), the Arizona Department of Health Services (contract 211002, Arizona Alzheimer's Research Center), the Arizona Biomedical Research Commission (contracts 4001, 0011, 05-901 and 1001 to the Arizona Parkinson's Disease Consortium), and the Michael J. Fox Foundation for Parkinson's Research. Dr. Thomas Beach is the principal investigator or main recipient for all the listed grants.

                Send correspondence to: Geidy E. Serrano, PhD, Banner Sun Health Research Institute, 10515 W Santa Fe Drive, Bldg. B, 3rd Floor, Sun City, AZ 85351. E-mail: Geidy.Serrano@ 123456bannerhealth.com .
                Article
                nlw047
                10.1093/jnen/nlw047
                7299435
                27297671
                11f5aa56-ea31-4c23-aeb6-b2738c1068b5
                © 2016 American Association of Neuropathologists, Inc. All rights reserved.

                This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License ( http://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial reuse, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com

                History
                Page count
                Pages: 7
                Funding
                Funded by: NIH, DOI 10.13039/100000002;
                Funded by: National Institute of Neurological Disorders and Stroke, DOI 10.13039/100000065;
                Award ID: U24 NS072026
                Funded by: National Institute on Aging, DOI 10.13039/100000049;
                Award ID: P30 AG19610
                Funded by: Arizona Department of Health Services, DOI 10.13039/100007306;
                Award ID: 211002
                Funded by: Arizona Biomedical Research Commission, DOI 10.13039/100008335;
                Award ID: 4001
                Award ID: 0011
                Award ID: 05-901
                Award ID: 1001
                Funded by: Michael J. Fox Foundation for Parkinson's Research, DOI 10.13039/100000864;
                Categories
                Original Articles

                amyloid plaque,brain weight,cognition,neuritic plaque,neurofibrillary tangle,phosphorylated tau

                Comments

                Comment on this article